Recent studies have shed light on the critical role of cardiolipin in mitochondrial function and how its deficiency can lead to severe health issues in Barth syndrome. For instance, one study ...

A US Food and Drug Administration (FDA) advisory committee (AdCom) has voted in support of Stealth Biotherapeutics’ ...

If approved, this would be the first marketing authorization for elamipretide, a first-in-class mitochondria-targeted therapeutic, and the first FDA-approved therapy for Barth syndrome.